Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study

IntroductionNeoadjuvant chemoimmunotherapy (NACI) has drawn considerable attention in Head and neck squamous cell carcinoma (HNSCC) owing to its potential in functional preservation and treatment-failure reduction. Yet whether the surgical extent can be narrowed following NACI is largely debatable d...

Full description

Saved in:
Bibliographic Details
Main Authors: Dikan Wang, Fanning Zeng, Sien Zhang, Wanming Hu, Yahui Wang, Daiqiao Ouyang, Bin Zeng, Guozhong Zeng, Jingyuan Li, Guiqing Liao, Yujie Liang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1627442/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849236538226900992
author Dikan Wang
Dikan Wang
Fanning Zeng
Fanning Zeng
Sien Zhang
Sien Zhang
Wanming Hu
Yahui Wang
Yahui Wang
Daiqiao Ouyang
Daiqiao Ouyang
Bin Zeng
Bin Zeng
Guozhong Zeng
Guozhong Zeng
Jingyuan Li
Jingyuan Li
Guiqing Liao
Guiqing Liao
Yujie Liang
Yujie Liang
author_facet Dikan Wang
Dikan Wang
Fanning Zeng
Fanning Zeng
Sien Zhang
Sien Zhang
Wanming Hu
Yahui Wang
Yahui Wang
Daiqiao Ouyang
Daiqiao Ouyang
Bin Zeng
Bin Zeng
Guozhong Zeng
Guozhong Zeng
Jingyuan Li
Jingyuan Li
Guiqing Liao
Guiqing Liao
Yujie Liang
Yujie Liang
author_sort Dikan Wang
collection DOAJ
description IntroductionNeoadjuvant chemoimmunotherapy (NACI) has drawn considerable attention in Head and neck squamous cell carcinoma (HNSCC) owing to its potential in functional preservation and treatment-failure reduction. Yet whether the surgical extent can be narrowed following NACI is largely debatable due to a potential non-centripetal tumor regression may result in scattered microfoci residing beyond the narrowed margin.MethodsIn this pilot study, we characterized the tumor regression pattern in a post-NACI HNSCC cohort using a whole-mount histopathological approach. The MRI examinations before and after NACI were used to evaluate the objective response rate (ORR).ResultsOf the 52 patients enrolled, the ORR was 75%. Pathological complete response (pCR) rate was 15.4%, and the major pathological response (MPR) rate was 40.4%. Two major regression patterns were identified in whole-mount tumor sections, centripetal regression and non-centripetal regression. Centripetal regression was observed in 37 patients (71.2%) and was subcategorized into complete regression (Ia, 15.4%), unifocal centripetal regression (Ib, 36.5%), and multifocal centripetal regression (Ic, 19.2%). Non-centripetal regression was seen in 15 patients (28.8%) and was subcategorized into scattered regression (IIa, 25.0%) and non-regression (IIb, 3.8%). Moreover, we found a pre-NACI CPS higher than 20 or post-NACI (18)F-FDG SUVmax reduction exceeding 50% were potential predictive factors for the centripetal regression pattern.DiscussionWe revealed for that centripetal regression was the predominant pattern of regression after NACI in HNSCC. Hence, our data presumably supports a reduced surgical extent in post-NACI HNSCC patients. Future studies should focus on identifying accurate predictive factors for the regression pattern, which may eventually assist in risk stratification and surgical decision making.ConclusionsThe pattern of tumor pathological regression after NACI for HNSCC is mainly divided into centripetal and non-centripetal regression, with the former accounting for the major portion of the regression.
format Article
id doaj-art-9bbdc76bb9de44c2b26f6252bf5840c6
institution Kabale University
issn 1664-3224
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-9bbdc76bb9de44c2b26f6252bf5840c62025-08-20T04:02:13ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16274421627442Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot studyDikan Wang0Dikan Wang1Fanning Zeng2Fanning Zeng3Sien Zhang4Sien Zhang5Wanming Hu6Yahui Wang7Yahui Wang8Daiqiao Ouyang9Daiqiao Ouyang10Bin Zeng11Bin Zeng12Guozhong Zeng13Guozhong Zeng14Jingyuan Li15Jingyuan Li16Guiqing Liao17Guiqing Liao18Yujie Liang19Yujie Liang20Hospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaDepartment of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, Guangdong, ChinaIntroductionNeoadjuvant chemoimmunotherapy (NACI) has drawn considerable attention in Head and neck squamous cell carcinoma (HNSCC) owing to its potential in functional preservation and treatment-failure reduction. Yet whether the surgical extent can be narrowed following NACI is largely debatable due to a potential non-centripetal tumor regression may result in scattered microfoci residing beyond the narrowed margin.MethodsIn this pilot study, we characterized the tumor regression pattern in a post-NACI HNSCC cohort using a whole-mount histopathological approach. The MRI examinations before and after NACI were used to evaluate the objective response rate (ORR).ResultsOf the 52 patients enrolled, the ORR was 75%. Pathological complete response (pCR) rate was 15.4%, and the major pathological response (MPR) rate was 40.4%. Two major regression patterns were identified in whole-mount tumor sections, centripetal regression and non-centripetal regression. Centripetal regression was observed in 37 patients (71.2%) and was subcategorized into complete regression (Ia, 15.4%), unifocal centripetal regression (Ib, 36.5%), and multifocal centripetal regression (Ic, 19.2%). Non-centripetal regression was seen in 15 patients (28.8%) and was subcategorized into scattered regression (IIa, 25.0%) and non-regression (IIb, 3.8%). Moreover, we found a pre-NACI CPS higher than 20 or post-NACI (18)F-FDG SUVmax reduction exceeding 50% were potential predictive factors for the centripetal regression pattern.DiscussionWe revealed for that centripetal regression was the predominant pattern of regression after NACI in HNSCC. Hence, our data presumably supports a reduced surgical extent in post-NACI HNSCC patients. Future studies should focus on identifying accurate predictive factors for the regression pattern, which may eventually assist in risk stratification and surgical decision making.ConclusionsThe pattern of tumor pathological regression after NACI for HNSCC is mainly divided into centripetal and non-centripetal regression, with the former accounting for the major portion of the regression.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1627442/fullchemo-immunotherapyneoadjuvant therapyhead and neck squamous cell carcinoma (HNSCC)regression patternpathological response
spellingShingle Dikan Wang
Dikan Wang
Fanning Zeng
Fanning Zeng
Sien Zhang
Sien Zhang
Wanming Hu
Yahui Wang
Yahui Wang
Daiqiao Ouyang
Daiqiao Ouyang
Bin Zeng
Bin Zeng
Guozhong Zeng
Guozhong Zeng
Jingyuan Li
Jingyuan Li
Guiqing Liao
Guiqing Liao
Yujie Liang
Yujie Liang
Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study
Frontiers in Immunology
chemo-immunotherapy
neoadjuvant therapy
head and neck squamous cell carcinoma (HNSCC)
regression pattern
pathological response
title Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study
title_full Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study
title_fullStr Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study
title_full_unstemmed Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study
title_short Pathological regression patterns following neoadjuvant chemo-immunotherapy in head and neck squamous cell carcinoma: a pilot study
title_sort pathological regression patterns following neoadjuvant chemo immunotherapy in head and neck squamous cell carcinoma a pilot study
topic chemo-immunotherapy
neoadjuvant therapy
head and neck squamous cell carcinoma (HNSCC)
regression pattern
pathological response
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1627442/full
work_keys_str_mv AT dikanwang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT dikanwang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT fanningzeng pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT fanningzeng pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT sienzhang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT sienzhang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT wanminghu pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT yahuiwang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT yahuiwang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT daiqiaoouyang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT daiqiaoouyang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT binzeng pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT binzeng pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT guozhongzeng pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT guozhongzeng pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT jingyuanli pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT jingyuanli pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT guiqingliao pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT guiqingliao pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT yujieliang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy
AT yujieliang pathologicalregressionpatternsfollowingneoadjuvantchemoimmunotherapyinheadandnecksquamouscellcarcinomaapilotstudy